Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alzheimer Disease AND Aggression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Alzheimer Disease AND Aggression. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-001127-32 Sponsor Protocol Number: ACP-103-032 Start Date*: 2016-09-19
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer’s Disease
    Medical condition: Agitation and Aggression in Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001128-78 Sponsor Protocol Number: ACP-103-033 Start Date*: 2017-03-21
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer’s Disease
    Medical condition: Agitation and Aggression in Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000217-30 Sponsor Protocol Number: 3098012 Start Date*: 2015-06-16
    Sponsor Name:Orion Corporation
    Full Title: EFFICACY OF ORM-12741 ON AGITATION/AGGRESSION SYMPTOMS IN PATIENTS WITH ALZHEIMER’S DISEASE: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTRE STUDY OF 12 WEEKS
    Medical condition: The agitation/aggression symptoms in patients with Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FI (Completed) PL (Completed) BG (Completed) RO (Suspended by CA) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000503-17 Sponsor Protocol Number: 331-12-284 Start Date*: 2015-01-29
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Flexible Dosing of Brexpiprazole (OPC-34712) in the Treatme...
    Medical condition: Agitation Associated with Dementia of the Alzheimer’s Type
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Prematurely Ended) SI (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-000860-10 Sponsor Protocol Number: 10729 Start Date*: 2006-06-30
    Sponsor Name:H. Lundbeck A/S
    Full Title: An Open-Label Study Investigating the Specific Effects of Memantine in Institutionalised Patients with Alzheimer’s Disease
    Medical condition: Effects of memantine treatment in institutionalised patients with Alzheimer's Disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-000504-41 Sponsor Protocol Number: 331-12-283 Start Date*: 2013-12-10
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: Country-specific protocol amendment for Germany entitled: A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2...
    Medical condition: Agitation Associated with Dementia of the Alzheimer’s Type
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2007-004897-26 Sponsor Protocol Number: Lu-11829A Start Date*: 2008-05-23
    Sponsor Name:King's College London [...]
    1. King's College London
    2. North Essex Partnership NHS Foundation Trust
    Full Title: Memantine for the Long Term Management of Neuropsychiatric Symptoms in Alzheimer's disease - MAIN-AD
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004299-20 Sponsor Protocol Number: ELND005-AG201 Start Date*: 2013-04-25
    Sponsor Name:Transition Therapeutics Ireland Ltd
    Full Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheime...
    Medical condition: Agitation and Aggression in Moderate to Severe Alzheimer’s Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-005524-15 Sponsor Protocol Number: ELND005-AG251 Start Date*: 2013-09-03
    Sponsor Name:Elan Pharma International Ltd
    Full Title: A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease.
    Medical condition: Agitation and Aggression in Moderate to severe Alzheimer's Disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003405-22 Sponsor Protocol Number: CTP3S1502HT6 Start Date*: 2022-09-02
    Sponsor Name:Suven Life Sciences Ltd.
    Full Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SUVN-502) for the Tre...
    Medical condition: Agitation with Dementia of the Alzheimer's Type
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003940-19 Sponsor Protocol Number: 331-14-213 Start Date*: 2018-08-06
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo controlled, 2 Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatme...
    Medical condition: Agitation Associated With Dementia of the Alzheimer’s Type
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) ES (Ongoing) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-005289-39 Sponsor Protocol Number: GER001-02-02 Start Date*: 2012-05-16
    Sponsor Name:Radboud university medical center
    Full Title: Efficacy and safety of delta-9-tetrahydrocannabinol (delta-THC) in behavioural disturbances and pain in dementia
    Medical condition: Subjects with mild to severe Alzheimer's dementia and/or vascular dementia with behavioural disturbances, with at least agitation, aggression or aberrant motor disturbances.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    16.1 10029205 - Nervous system disorders 10057678 Vascular dementia PT
    16.1 10018065 - General disorders and administration site conditions 10033371 Pain PT
    16.1 10029205 - Nervous system disorders 10012267 Dementia PT
    16.1 10037175 - Psychiatric disorders 10066842 Behavioural and psychiatric symptoms of dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002140-88 Sponsor Protocol Number: CL04-ORY-2001 Start Date*: 2018-09-06
    Sponsor Name:Oryzon Genomics S.A.
    Full Title: An unicenter, open-label, 1-arm, 8-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in adult population with Alzheimer’s Disease (AD), Lewy Body Dementia (LBD)...
    Medical condition: Agression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10001488 Aggression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-001436-54 Sponsor Protocol Number: CL06-ORY-2001 Start Date*: 2019-06-05
    Sponsor Name:Oryzon Genomics S. A.
    Full Title: A single-center, open-label, single-arm, 13-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in Alzheimer’s Disease (AD) – REIMAGINE-AD
    Medical condition: Aggression in Alzheimer’s Disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000243-33 Sponsor Protocol Number: FARM68SY5C Start Date*: 2008-09-24
    Sponsor Name:ISTITUTO SUPERIORE DI SANITA'
    Full Title: Alzheimer disease and antipsycotics: a long term multicenter randomized clinical trial
    Medical condition: BPSD in Alzheimer disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004209 Behaviour and socialisation disturbances HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020008-31 Sponsor Protocol Number: ACP-103-019 Start Date*: 2013-10-25
    Sponsor Name:ACADIA Pharmaceuticals Inc
    Full Title: A Single center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer’s Disease
    Medical condition: Psychosis associated with Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001056-17 Sponsor Protocol Number: 3606 Start Date*: 2020-08-14
    Sponsor Name:Kings's College London [...]
    1. Kings's College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: A randomised feasibility trial investigating Sativex® for the treatment of the Agitation & Aggression (A/A) in Alzheimer’s Dementia.
    Medical condition: Clinically significant agitation in Alzheimer's Diseases
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10001499 Agitation mental LLT
    20.0 10037175 - Psychiatric disorders 10001497 Agitation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-005087-93 Sponsor Protocol Number: Start Date*: 2006-11-17
    Sponsor Name:East Kent Hospitals NHS Trust
    Full Title: A randomized double blind placebo controlled trial of Memantine in the treatment of Agitation in Alzheimers Dementia
    Medical condition: Alzheimers dementia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002455-29 Sponsor Protocol Number: 15-AVP-786-303 Start Date*: 2018-07-31
    Sponsor Name:Avanir Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Long-term, Extension Study of the Safety and Efficacy of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the Treatment of Agitation...
    Medical condition: Agitation Associated with Dementia of the Alzheimer's Type
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10001497 Agitation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) FR (Completed) PL (Completed) BG (Completed) CZ (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001339-38 Sponsor Protocol Number: 17-AVP-786-305 Start Date*: 2018-01-22
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/qui...
    Medical condition: Agitation Associated with Dementia of the Alzheimer's Type
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10001497 Agitation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) FR (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 08:44:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA